Conservative treatment of patients after peripheral arterial reconstruction for chronic critical limb ischemia

• Maxim N. Muravyov
• Vladislav A. Panfilov
• Konstantin V. Romanenko
• Maxim R. Kuznetsov
• Anatoly O. Virganskiy

Abstract

Background. Conservative management of patients after reconstructive vascular operations remains an important and widely discussed problem of modern medicine.

Objective. This study was aimed at evaluating efficacy and safety of combined administration of aspirin and low-dose rivaroxaban in patients with atherosclerosis who underwent reconstructive operations on arteries below the inguinal ligament for chronic critical lower limb ischemia.

Patients and methods. Our prospective cohort study included a total of 182 patients with atherosclerosis and chronic critical lower limb ischemia. The patients’ age ranged from 40 to 95 years (mean age 65.3±8.1 years). The period of the study was from 2018 to 2021. All patients underwent femoropopliteal bypass graft surgery with a distal anastomosis both above and below the knee-joint fissure, with either a reversed autovein or a synthetic graft used as a shunt. The patients were divided into 4 groups depending on the type of operation and prescribed therapy in the postoperative period. Control was carried out by means of clinical examination and duplex ultrasound angioscanning of lower-limb arteries after 30 days, as well as at 3, 6 and 12 postoperative months.

Results. An unfavorable clinical outcome was defined as the development of either single or various combinations of such conditions as acute limb ischemia, major amputation, shunt thrombosis, acute myocardial infarction, acute cerebrovascular accident, cardiovascular death. They were reveled in the remote period after surgery (from 30 days to 12 month) in 4 (8.3%) Group 1 patients, 6 (13.6%) Group 2 patients, 6 (13.3%) Group 3 patients and in 11 (24.4%) Group 4 patients. Besides, there was 1 (2.6%) major gastrointestinal bleeding in Group 2, with no significant hemorrhagic events revealed in other groups (p=NS).

Conclusion. Low-dose rivaroxaban combined with aspirin proved effective in preventing major adverse limb events and safe as to hemorrhagic complications compared with a combination of aspirin and clopidogrel in patients after revascularization of lower extremities for chronic critical limb ischemia.

Funding. The study had no financial support.

Conflict of interest. The authors declare no conflicts of interest.

Authors’ contribution. Study conception and design – Virgansky A.O., Panfilov V.A., Muravyov M.N.; data collection and handling – Muravyov M.N., Romanenko K.V.; statistical processing – Muravyov M.N.; draft manuscript preparation – Muravyov M.N., Panfilov V.A.; manuscript revision – Virgansky A.O., Panfilov V.A., Kuznetsov M.R.

For citation: Muravyov M.N., Panfilov V.A., Romanenko K.V., Kuznetsov M.R., Virgansky A.O. Conservative treatment of patients after peripheral arterial reconstruction for chronic critical limb ischemia. Angiology and Vascular Surgery. Journal named after Academician A.V. Pokrovsky. 2025; 31 (1): 76–85. DOI: https://doi.org/10.33029/1027-6661-2025-31-1-76-85

Keywords: peripheral artery atherosclerosis; critical lower limb ischemia; femoropopliteal bypass; lower limb amputation; anticoagulants; antiplatelet drugs

References

1. Fowkes F.G.R., Rudan D., Rudan I., et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis. Lancet. 2013; 382 (9901): 1329–40. DOI: https://doi.org/10.1016/S0140-6736(13)61249-0

2. Global status report on noncommunicable diseases 2010. Geneva Switzerland: World Health Organization. 2011.

3. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385 (9963): 117–171. DOI: https://doi.org/10.1016/S0140-6736(14)61682-2

4. Federal State Statistics Service (ROSSTAT) [Electronic resource]. https://rosstat.gov.ru/folder/13721 (in Russian)

5. Criqui M.H., Aboyans V. Epidemiology of Peripheral Artery Disease. Circulation Research. 2015; 116 (9): 1509–26. DOI: https://doi.org/10.1161/CIRCRESAHA.116.303849

6. Acute myocardial infarction with ST segment elevation electrocardiogram. Clinical guideline. 2020. (in Russian)

7. Acute myocardial infarction without ST segment elevation electrocardiogram. Clinical guideline. 2020. (in Russian)

8. Stable coronary heart disease. Clinical guideline. 2020. (in Russian)

9. Ischemic stroke and transient ischemic attack in adults. Clinical guideline. 2021. (in Russian)

10. Belch J.J.F., Dormandy J. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. Journal of Vascular Surgery. 2010; 52 (4): 825–833.e2. DOI: https://doi.org/10.1016/j.jvs.2010.04.027

11. APPRAISE Steering Committee and Investigators; Alexander J.H., Becker R.C., Bhatt D.L., et al. Apixaban, an oral, direct, selective factor xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: Results of the apixaban for prevention of acute ischemic and safety events (APPRAISE) trial. Circulation. Circulation. 2009; 119 (22): 2877–2885. DOI: https://doi.org/10.1161/CIRCULATIONAHA.108.832139

12. Alexander J.H., Lopes R.D., James S., et al. Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. New England Journal of Medicine. 2011; 365 (8): 699–708. DOI: https://doi.org/10.1056/NEJMoa1105819

13. Eikelboom J.W., Connolly S.J., Bosch J., et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine. 2017; 377 (14): 1319–1330. DOI: https://doi.org/10.1056/NEJMoa1709118

14. Vanassche T., Verhamme P., Anand S.S., et al. Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. European Journal of Preventive Cardiology. 2020; 27 (3): 296–307. DOI: https://doi.org/10.1177/2047487319882154

15. Arakelyan V.S. Key aspects of drug therapy in vascular surgery. Angiology and Vascular Surgery. 2021; 27 (4): 17–25. (in Russian)

16. Russian clinical guidelines for the treatment of patients with critical lower limb ischemia. 2023. (in Russian)

17. Conte M.S., Bradbury A.W., Kolh P., et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. Journal of Vascular Surgery. 2019; 69 (6S): 3S–125S.e40. DOI: https://doi.org/10.1016/j.jvs.2019.02.016

18. National guidelines for the diagnosis and treatment of diseases of the arteries of the lower extremities. Clinical guideline. 2019. (in Russian)

19. Graziansky N.A. Antiplatelet therapy in coronary heart disease. Some challenges and achievements. Atherothrombosis. 2010; 1 (4): 1–69. (in Russian)

20. Kuliczkowski W., Witkowski A., Polonski L., et al. Interindividual variability in the response to oral antiplatelet drugs: A position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. European Heart Journal. 2009; 30 (4): 426–35. DOI: https://doi.org/10.1093/eurheartj/ehn562

21. Gori A.M., Marcucci R., Migliorini A., et al. Incidence and Clinical Impact of Dual Nonresponsiveness to Aspirin and Clopidogrel in Patients With Drug-Eluting Stents. Journal of the American College of Cardiology. 2008; 52 (9): 734–9. DOI: https://doi.org/10.1016/j.jacc.2008.05.032

22. Hummel T., Meves S.H., Breuer-Kaiser A., et al. Perioperative changes of response to antiplatelet medication in vascular surgery patients. PLoS One. 2020; 15 (12): e0244330. DOI: https://doi.org/10.1371/journal.pone.0244330

23. Gori A.M., Marcucci R., Migliorini A., et al. Incidence and Clinical Impact of Dual Nonresponsiveness to Aspirin and Clopidogrel in Patients With Drug-Eluting Stents. Journal of the American College of Cardiology. 2008; 52 (9): 734–9. DOI: https://doi.org/10.1016/j.jacc.2008.05.032

24. Johnson W.C., Williford W.O. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients peripheral arterial bypass procedures: A prospective randomized study. Journal of Vascular Surgery. 2002; 35 (3): 413–21. DOI: https://doi.org/10.1067/mva.2002.121847

25. Bossard M., Granger C.B., Tanguay J.F., et al. Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Journal of the American Heart Association. 2017; 6 (11): e006577. DOI: https://doi.org/10.1161/JAHA.117.006577